Shah Capital has announced the withdrawal of its campaign against the re-election of three directors on Novavax's board following the COVID-19 vaccine maker's licensing deal with Sanofi. The deal, signed on May 10, entails Sanofi taking a 4.9% stake in Novavax for $70 million at a substantial valuation, including an upfront cash payment of $500 million and future...
Novavax shares ( NASDAQ:NVAX ) surged over 130% after a $1.4 billion deal with Sanofi was announced to commercialize its Covid vaccine and develop a new combination shot for protecting against the flu and Covid. The biotech firm announced a licensing agreement with Sanofi to sell Novavax’s Covid vaccine worldwide, with Sanofi paying Novavax $500 million upfront...
In a quest to reclaim lost ground and assert its presence in the competitive COVID-19 vaccine market, Novavax (NASDAQ: NASDAQ:NVAX ) charts a strategic course aimed at improving commercial performance and gaining market share from industry giants Pfizer (PFE.N) and Moderna (MRNA.O). Despite facing headwinds and a larger-than-expected fourth-quarter loss, Novavax...
Similarities can be seen in red,yellow,green The breakabove the fib circle level, which has previously been seen as a strong resistance point is an extremely good sign along with the possible development of a vaccine for a new variant (if the current vaccine isn't effective) NVAX looks bullish